Female genital schistosomiasis-related infertility and gynecological manifestations among women living in countries endemic for urogenital schistosomiasis in Africa: systematic review and meta-analysis protocol Authors: Francisca Happy Ametor, Morrison Asiamah, David Owiredu, Kwadwo Owusu Akuffo, Mercy Monde Imakando, Anthony Danso-Appiah Published: 2026 ABSTRACT IntroductionFemale genital schistosomiasis (FGS), affecting over 56 million women and girls, is a neglected tropical disease with substantial public health implications. Existing evidence on its impact on reproductive health, particularly infertility, is limited and, in most cases, inconclusive. This systematic review aims to gather evidence on the magnitude of FGS-related gynecological manifestations and infertility among females of reproductive age living in countries across Africa.MethodsWe will search PubMed, CINAHL, LILACS, Google Scholar, Web of Science, and African Journals Online (AJOL) from inception to 31st August 2026, without language restrictions, using terms such as “female genital schistosomiasis”, “FGS”, and “infertility” together with all applicable alternative terms nested with the appropriate Boolean operators. We will also search gray sources such as conference proceedings, dissertations, WHO databases, and preprint repositories for studies. The reference lists of relevant studies will be hand-searched for additional studies potentially missed by our searches. Retrieved studies will be collated and deduplicated using EndNote and exported to Rayyan QCRI for screening. At least two reviewers will independently select studies, extract data, and assess the quality of the included studies using validated tools, resolving disagreements through discussion. We will use pooled proportions for non-comparative studies and odds ratios or risk ratios for comparative studies reporting categorical data, while mean and mean difference (MD) will be used to summarize continuous data. All estimates will be reported with their corresponding 95% confidence intervals (CIs). Random-effects or fixed-effect meta-analysis models will be employed, depending on the extent of heterogeneity between studies. The heterogeneity will be assessed graphically for overlapping CIs and statistically using the I2 statistic. We will conduct sub-group analyses when there is significant heterogeneity, and sensitivity analyses to assess the robustness of pooled estimates.Systematic review registrationPROSPERO CRD42023449271Supplementary InformationThe online version contains supplementary material available at 10.1186/s13643-026-03214-w. Background Female genital schistosomiasis (FGS), caused by worms collectively called the blood fluke, is an important public health problem affecting millions of girls and women in reproductive age but seriously neglected [1–3]. The pathogenesis is complex, involving several stages, and starts after exposure to cercariae-infested freshwater [4]. The infective cercariae penetrate the skin barrier, enter the bloodstream, and migrate to the venous plexus of the female reproductive organs within the pelvis [5]. There, the cercariae mature, female and male pair up, mate and release numerous eggs that traverse the blood vessels whilst migrating to tissues of the female reproductive organs [6]. The disease and its complications are not caused by the parasites themselves, but the eggs deposited in the female reproductive organs and structures that get trapped in the tissues [4, 7]. The eggs that get trapped in tissues trigger inflammatory sequelae, resulting in neovascularization and sandy patches that initiate pathology development [8]. Whilst egg load is an important factor in determining the severity of FGS-related morbidity, a host of factors interact to shape the clinical presentation and outcomes of the disease [9]. These factors include duration of infection, host immune response and access to healthcare services for diagnosis and treatment [10]. The statistics on the global burden of female genital schistosomiasis are scarce, as the condition is underreported, misdiagnosed, and underestimated [7, 11, 12]. Nonetheless, the fragmented estimates suggest 30 to 75% of S. haematobium cases acquired in childhood in girls result in FGS [13, 14]. In Sub-Saharan Africa, the prevalence of FGS is estimated to be 11–75%, which translates into up to 56 million, with a further one-third projected to become infected in the next decade [13–15]. This makes FGS an emerging neglected tropical disease (NTD) of significant public health importance [1]. Early detection and appropriate management of FGS are crucial in attempts to reduce morbidity and improving the outcomes of affected individuals. FGS-related complications may be acute and short-lived, but are often long-term, leading to chronic inflammation and scarring in the reproductive organs [16, 17]. The damage, particularly to reproductive organs such as the uterus and ovaries, can impair the obstetric and gynecologic functions of the woman [18, 19], thereby increasing the risk of infertility [17, 20]. The disease has also been associated with poor reproductive health outcomes [16], with an estimated 3.6% ectopic pregnancy and 41% cases of infertility attributed to the disease [21]. Some epidemiological studies have assessed the possible association between FGS and reduced fertility rates, though the direct causal pathways remain to be fully elucidated [21–24]. For instance, a study conducted in Zimbabwe reported a significant difference in the prevalence of infertility (19.6%) among women with FGS compared to 4.4% without FGS [25]. Similarly, 7% cases of infertility were reported among reproductive-aged women with FGS in Tanzania [26]. Another study identified that a third of S. haematobium infected women of reproductive age reported fertility problems [27]. Another complication of FGS is the increased risk for HIV, estimated at up to fourfold, a consequence of an altered cervical mucosal gene expression and decreased interleukin 15 levels [8, 28–33]. Although FGS is prevalent in many regions of Sub-Saharan Africa with significant consequences for reproductive and mental health, it is often overlooked by public health professionals and policymakers [6]. This is mainly due to a lack of capacity in the healthcare system to effectively diagnose and manage FGS-related problems [1, 34, 35]. As a result, its true burden has not yet been assessed or reviewed as part of the schistosomiasis burden by the Global Burden of Diseases Study [11]. Accurate disease burden information is difficult to obtain due to the disease’s low clinical awareness among healthcare workers [36]. The neglect has also resulted in very few studies being conducted in this area, particularly on the long-term consequences of FGS on women of reproductive age [37]. The existing studies on FGS have focused primarily on the prevalence, epidemiology and diagnosis, with very few studies looking at association between FGS and infertility [19, 21]. While these studies have helped to deepen the understanding of FGS as a serious public health problem, none investigated the relationship between FGS and infertility or FGS-related gynecological manifestations. There is a substantial gap in existing epidemiological data on the number of people at risk of FGS [1]. Given the fragmented data, very little attention has been paid to the disease [36] making it one of the most neglected sexual and reproductive health issues [2]. The reasons for the neglect of the disease include a lack of estimates highlighting the burden of the disease, misdiagnosis and underreporting of the condition [7, 11, 12]. Additionally, the available data is scattered making FGS unnoticed and prioritized. The existing empirical data on the association between FGS and its impact on reproductive health, particularly infertility, is limited and in most cases, inconclusive [17, 21, 26]. From the exploratory searches conducted prior to registration of the protocol, no systematic review has comprehensively looked at FGS-related gynecological presentations, or importantly, infertility across countries in Africa. Therefore, synthesizing the available evidence will help to highlight the burden of FGS, determine the proportion with reported infertility, assess the strength of the association between FGS and infertility and gynecological manifestations among women in schistosomiasis-endemic settings in Africa. An overarching goal is that this review will identify knowledge gaps and inform policy, practice and priorities in an effort to combat FGS and related public health consequences. This systematic review of FGS-related infertility significantly impacts multiple Sustainable Development Goals (SDGs). Firstly, by synthesizing existing evidence on FGS, awareness would be created among relevant stakeholders, particularly policymakers and researchers, about FGS as a significant public health problem. This could culminate in improved diagnosis, treatment, and prevention strategies, thereby accelerating efforts towards the attainment of SDG 3.3, to end NTDs and combat waterborne diseases. This will ultimately enhance good health and well-being underpinned in SDG 3. Besides, by highlighting the disproportionate impact of FGS-related complications such as infertility, ectopic pregnancy, miscarriage, etc., on women and girls, the conclusions of this review can support advocacy and innovative interventions to promote gender equality through equitable access to healthcare services, education, and resources (the pivot to SDG 5). Thirdly, by shedding light on inequalities in healthcare access and outcomes, particularly in marginalized communities where FGS is mostly endemic, can help advocacy for interventions that prioritize the needs of vulnerable women and reduce disparities in health outcomes which SDG 10 attempts to address. Finally, this review aims to distill evidence at the highest level to inform evidence-based policies and programs aimed at improving reproductive health outcomes and advancing the SDGs. Methods This systematic review protocol has been prepared in accordance with guidelines specified in the Cochrane Handbook [38], reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol (PRISMA-P) guidelines (Additional file 1) [39] and followed the methods reported in earlier works [40–51]. The electronic databases and other sources searched and the flow of studies will be reported using the PRISMA Flow diagram (Additional file 2) [52]. The full review will be reported in accordance with the PRISMA guidelines [53]. Criteria for considering studies for this review Types of studies All observational studies (cohort, case-control, cross-sectional, and longitudinal studies, including case reports and case series) conducted in schistosomiasis-endemic settings and reporting proportion or prevalence of FGS and reproductive health outcomes will be eligible for inclusion. This is an exposure review, not a review of intervention effectiveness, and therefore, randomized controlled trials (RCTs) are not the focus. However, if an RCT reports a baseline number of cases from a well-defined sample and denominator to allow the calculation of proportion or incidence of FGS and FGS-related gynecological presentations such as pain during sex, bleeding, etc., or infertility, such an RCT will be eligible for inclusion. Although reviews will not be eligible for inclusion, we will go through them, and if any potentially eligible studies missed by our searches are identified, we will include them. Where the study reports a country or regional estimate without a well-defined sample (a representative sample or sub-sample of the source population) or data from secondary analysis, it will not be eligible for inclusion. If the data from multi-country studies cannot be disaggregated due to the lumping together of results, these studies will be excluded from the meta-analysis. Opinions and commentaries on FGS and related reproductive health outcomes will not be eligible for inclusion in this review. Population Women of reproductive age, defined as aged between 15 and 50 years, who live in a schistosomiasis-endemic country in Africa and have been diagnosed as having FGS, will be eligible for inclusion. Women who have received irreversible (permanent) procedures that could make them infertile or whose diagnosis cannot be confirmed will be excluded. Exposure The exposure of interest is FGS, diagnosed clinically through gynecological examination and/or by laboratory tests such as microscopy for Schistosoma eggs in the urine, or by polymerase chain reaction (PCR) [54–56]. Participants whose diagnosis of FGS or infertility could not be confirmed will be excluded from this study. Comparator This is not a comparative systematic review; however, where data permit, we will perform sub-group comparisons of key variables such as location, region, age, etc. Outcomes Primary outcomes Proportion diagnosed of FGS.Proportion or incidence of FGS-related infertility. Proportion diagnosed of FGS. Proportion diagnosed of FGS. Proportion or incidence of FGS-related infertility. Proportion or incidence of FGS-related infertility. Secondary outcomes FGS-related gynecological symptoms.FGS-related clinical presentations or complications such as pain during sex, vaginal bleeding, etc. FGS-related gynecological symptoms. FGS-related gynecological symptoms. FGS-related clinical presentations or complications such as pain during sex, vaginal bleeding, etc. FGS-related clinical presentations or complications such as pain during sex, vaginal bleeding, etc. Searches All relevant studies (published and unpublished) will be retrieved through searches on PubMed, CINAHL, LILACS and Google Scholar from inception to 31 st August 2026, without language restriction. The key search terms “female genital schistosomiasis”, “FGS”, “schistosomiasis”, “schistosoma”, “schistosome”, and “infertility”, together with all applicable alternative terms, will be linked with Boolean operators to generate a comprehensive search strategy. The names of all the endemic countries in Africa will be included as search terms. The search strategy will be piloted on PubMed, refined and tailored to other databases. The searches will be extended to African Index Medicus (AIM), African Journals Online (AJOL), Cochrane Central, Preprint Repositories (such as MedRXIV), and Dissertation Databases (such as ProQuest). The reference lists of relevant publications, including systematic reviews, will be hand-searched for additional studies. We will contact experts in the field of schistosomiasis for their knowledge about any ongoing or completed but unpublished studies. The PubMed search strategy has been presented in Table 1, which will be adapted for the other databases. Table 1PubMed Search Strategy (to be adapted for the other databases)SearchQuery#1Search: (((((((((("female genital schistosomiasis") OR (FGS)) OR ("Gynecological schistosomiasis")) OR ("Gynaecological schistosomiasis")) OR ("Schistosomiasis of the female genitalia")) OR ("genital bilharzia")) OR ("genital bilharziasis")) OR ("female genital bilharzia")) OR ("female genital bilharziasis")) OR ("bilharziasis of the female genital tract")) OR ("Schistosomiasis of the female genital tract")#2Search: ((((((((((((((((((((((((((Schistosom*) OR ("Schistosome infection*")) OR (Bilharzia*)) OR ("bloody urine")) OR (Haematuria)) OR (Hematuria)) OR (microhaematuria)) OR (microhematuria)) OR ("snail fever")) OR ("katayama fever")) OR ("trematode infection")) OR ("Schistosoma haematobium")) OR ("S. haematobium")) OR ("Schistosoma hematobium")) OR ("S. hematobium")) OR ("Schistosoma mansoni")) OR ("S. mansoni")) OR ("Schistosoma intercalatum")) OR ("S. intercalatum")) OR ("Schistosoma mekongi")) OR ("S. mekongi")) OR ("schistosome species")) OR ("blood fluke")) OR (schistosomiasis[MeSH Terms])) OR (schistosomiases[MeSH Terms])) OR (bilharzia[MeSH Terms])) OR (bilharzias[MeSH Terms])#3Search: ((((((((("Gynecological morbidity") OR ("Gynecological morbidity")) OR ("genital damage")) OR ("genital deformity")) OR (genital)) OR (gynecological)) OR (gynecological)) OR (genitalia)) OR ("genital fistula")#4Search: (#2) AND (#3)#5Search: (((((((((((infertility) OR (subfertility)) OR (sub-fertility)) OR (childlessness)) OR (sterility)) OR (sterile)) OR (infertile)) OR ("reproductive sterility")) OR (barrenness)) OR (infecundity)) OR ("reproductive dysfunction")) OR ("reproductive health")#6Search: (#1) AND (#5)#7Search: (#4) AND (#5)#8Search: ((((((((((((((((((((((((((((((((((((((((((((((((((((((((Africa) OR ("sub-Saharan Africa")) OR (Algeria)) OR (Angola)) OR (Benin)) OR (Bostwana)) OR ("Burkina Faso")) OR (Burundi)) OR ("Cabo Verde")) OR ("Cape Verde")) OR (Cameroon)) OR ("Central African Republic")) OR (Chad)) OR (Comoros)) OR ("Democratic Republic of Congo")) OR ("DR Congo")) OR (Congo)) OR (Djibouti)) OR (Egypt)) OR ("Equatorial Guinea")) OR (Eritrea)) OR (Eswatini)) OR (Ethiopia)) OR (Gabon)) OR (Gambia)) OR (Ghana)) OR (Guinea)) OR ("Guniea-Bissau")) OR ("Ivory Coast")) OR ("Cote d'Ivoire")) OR (Niger)) OR (Nigeria)) OR ("Sao Tome and Principe")) OR (Senegal)) OR (Seychelles)) OR ("Sierra Leone")) OR (Somalia)) OR (Kenya)) OR (Lesotho)) OR (Liberia)) OR (Libya)) OR (Madagascar)) OR (Malawi)) OR (Mali)) OR (Mauritania)) OR (Mauritius)) OR (Morocco)) OR (Mozambique)) OR (Namibia)) OR ("South Africa")) OR ("South Sudan")) OR (Tanzania)) OR (Togo)) OR (Tunisia)) OR (Uganda)) OR (Zambia)) OR (Zimbabwe)#9Search: (#6) AND (#8)#10Search: (#7) AND (#8) Table 1PubMed Search Strategy (to be adapted for the other databases)SearchQuery#1Search: (((((((((("female genital schistosomiasis") OR (FGS)) OR ("Gynecological schistosomiasis")) OR ("Gynaecological schistosomiasis")) OR ("Schistosomiasis of the female genitalia")) OR ("genital bilharzia")) OR ("genital bilharziasis")) OR ("female genital bilharzia")) OR ("female genital bilharziasis")) OR ("bilharziasis of the female genital tract")) OR ("Schistosomiasis of the female genital tract")#2Search: ((((((((((((((((((((((((((Schistosom*) OR ("Schistosome infection*")) OR (Bilharzia*)) OR ("bloody urine")) OR (Haematuria)) OR (Hematuria)) OR (microhaematuria)) OR (microhematuria)) OR ("snail fever")) OR ("katayama fever")) OR ("trematode infection")) OR ("Schistosoma haematobium")) OR ("S. haematobium")) OR ("Schistosoma hematobium")) OR ("S. hematobium")) OR ("Schistosoma mansoni")) OR ("S. mansoni")) OR ("Schistosoma intercalatum")) OR ("S. intercalatum")) OR ("Schistosoma mekongi")) OR ("S. mekongi")) OR ("schistosome species")) OR ("blood fluke")) OR (schistosomiasis[MeSH Terms])) OR (schistosomiases[MeSH Terms])) OR (bilharzia[MeSH Terms])) OR (bilharzias[MeSH Terms])#3Search: ((((((((("Gynecological morbidity") OR ("Gynecological morbidity")) OR ("genital damage")) OR ("genital deformity")) OR (genital)) OR (gynecological)) OR (gynecological)) OR (genitalia)) OR ("genital fistula")#4Search: (#2) AND (#3)#5Search: (((((((((((infertility) OR (subfertility)) OR (sub-fertility)) OR (childlessness)) OR (sterility)) OR (sterile)) OR (infertile)) OR ("reproductive sterility")) OR (barrenness)) OR (infecundity)) OR ("reproductive dysfunction")) OR ("reproductive health")#6Search: (#1) AND (#5)#7Search: (#4) AND (#5)#8Search: ((((((((((((((((((((((((((((((((((((((((((((((((((((((((Africa) OR ("sub-Saharan Africa")) OR (Algeria)) OR (Angola)) OR (Benin)) OR (Bostwana)) OR ("Burkina Faso")) OR (Burundi)) OR ("Cabo Verde")) OR ("Cape Verde")) OR (Cameroon)) OR ("Central African Republic")) OR (Chad)) OR (Comoros)) OR ("Democratic Republic of Congo")) OR ("DR Congo")) OR (Congo)) OR (Djibouti)) OR (Egypt)) OR ("Equatorial Guinea")) OR (Eritrea)) OR (Eswatini)) OR (Ethiopia)) OR (Gabon)) OR (Gambia)) OR (Ghana)) OR (Guinea)) OR ("Guniea-Bissau")) OR ("Ivory Coast")) OR ("Cote d'Ivoire")) OR (Niger)) OR (Nigeria)) OR ("Sao Tome and Principe")) OR (Senegal)) OR (Seychelles)) OR ("Sierra Leone")) OR (Somalia)) OR (Kenya)) OR (Lesotho)) OR (Liberia)) OR (Libya)) OR (Madagascar)) OR (Malawi)) OR (Mali)) OR (Mauritania)) OR (Mauritius)) OR (Morocco)) OR (Mozambique)) OR (Namibia)) OR ("South Africa")) OR ("South Sudan")) OR (Tanzania)) OR (Togo)) OR (Tunisia)) OR (Uganda)) OR (Zambia)) OR (Zimbabwe)#9Search: (#6) AND (#8)#10Search: (#7) AND (#8) PubMed Search Strategy (to be adapted for the other databases) Managing the search results and study selection The studies retrieved from the various databases will be collated and deduplicated using EndNote [57]. The deduplicated studies will be imported to Rayyan [58] for screening against the pre-specified eligibility criteria, guided by a pretested study selection flow chart (Fig. 1). Two members of the review team (FHA and ADA) will first screen the title and abstracts of studies to exclude the most obvious irrelevant studies to the review subject, then retrieve the full texts of studies found to be potentially relevant for further screening for inclusion in the review. All studies excluded at the full text stage will be reported in a table with reasons for exclusion. The PRISMA flow diagram will be used to document the sources of retrieved studies (database and non-database sources), the flow of studies during the selection process and reasons for exclusion. Any disagreements between the independent screening authors will be resolved through discussion.Fig. 1Study selection flowchart Study selection flowchart Data extraction and management A data extraction form will be developed, pretested and used to extract data independently by two reviewers (FHA and MA) and verified by ADA, who will help manage the data. Variables to be extracted include the first author’s name, year of publication, country study was conducted, study design, number of participants, participant age category, criteria for infection detection and disease diagnosis, number of participants assessed for FGS, baseline endemicity, proportions of study participants with FGS, gynecological symptoms, infertility and any other relevant outcomes. The extracted data will be entered and cleaned in Microsoft Excel version 16.0 and exported to STATA version SE18 [59] for analysis. Where necessary, we will use Review Manager version 5 [60] for the meta-analysis to generate the forest plots. Disagreements between reviewers will be resolved through discussion. Managing missing data The causes and patterns of missing data and the potential influence on the study will be assessed. However, rather than imputation of missing data, we will contact the primary authors of the studies for missing data. Where needed, we will request access to the raw data to enable us to extract missing or insufficient information. Assessment of quality of the included studies The included studies will be assessed independently by two reviewers (FHA and ADA) for risk of bias using the Cochrane tool for non-randomized studies of exposure (Robbins-E) assessment tool (Version 20 June 2023) (Additional file 3) based on a series of signaling questions across seven risk domains of bias: confounding, selection of study participants, measurement of exposure, post-exposure intervention, missing data, measurement of outcome, and selection of reported results. The signaling questions have response options “yes”, “probably yes”, “probably no”, “no”, and “no information”. The risk of bias will be judged as “low” for a domain with little or no concern about bias. Where there are some concerns about bias in a specific domain, but with no certainty of an important risk of bias, we will judge the domain as “some concerns”. For bias domains with some important bias concerns, we will judge as “high risk”. Studies with suspected serious bias will be judged as having a “very high risk of bias”. The results from the risk of bias assessment will be presented in a table with supporting statements from the primary studies. Disagreements between reviewers will be resolved through discussion. Strategy for data analysis The dependent variables, infertility and gynecological symptoms, will be measured as binary outcomes. The proportion of participants with FGS will be determined as a quotient of the number of participants with the outcome by the number of participants tested. The impact of the independent variables on infertility will be estimated in STATA 16, and the final meta-analysis will be run using random-effects model to obtain the pooled proportions, reported with their 95% confidence interval (CI). The results will be presented graphically as forest plots and tables, where necessary. Given that the number of women with FGS who experienced infertility is expected to be low (but clinically important), the association between FGS and infertility will be assessed using odds ratios (OR) and presented with their 95% CIs. If we find event rates to be high, we will employ risk ratio (RR) for estimating the association between FGS and infertility and present the estimates with their 95% CIs. Heterogeneity and sub-group analysis The variations in the studies included in the meta-analysis will be assessed using the I2 statistic, which measures the variation across studies due to heterogeneity rather than chance [61]. The level of heterogeneity will be classified as substantial if I2 is greater than 50% [62]. Cochran’s Q statistics and Tau-squared will be presented, and p < 0.05 will be used to assess the level of significance for heterogeneity. Where heterogeneity is detected to be substantial, the sources of the variation, such as the diagnostic approach for both FGS and infertility, endemicity, varying characteristics of the population under study, etc., will be determined, and sub-group analyses will be conducted to estimate their magnitude and impact on the overall effect estimate. Sensitivity analysis Where number of studies permits, we will perform sensitivity analysis to determine the robustness of the meta-analysis estimates on the quality domains of the included studies. Strengths and limitations This is the first review to synthesize comprehensive evidence on FGS gynecological manifestations and infertility. As a result, it will provide a complete understanding of the relationship between FGS and infertility and gynecological manifestations among women of reproductive age in Africa. By summarizing the available evidence, knowledge gaps can be identified, areas for further study highlighted, and strategies for prevention, diagnosis and treatment of FGS and related complications informed. The study will generate evidence that is applicable to a broader population of reproductive-aged women across countries in Africa endemic for schistosomiasis. This study may be limited by the quality of the included studies and the potential for publication bias that may result from under-reporting of studies with negative findings. Supplementary Information Additional file 1. PRISMA-P guidelines.Additional file 2. PRISMA flow diagram.Additional file 3. ROBINS E Assessment tool. Additional file 1. PRISMA-P guidelines. Additional file 2. PRISMA flow diagram. Additional file 3. ROBINS E Assessment tool.